EnHAnce PEEK Bunion System
Nvision Biomedical Technologies · Decision date Sep 18, 2026
What did the FDA decide?
The FDA recorded a substantially equivalent (SESE) decision on September 18, 2026 for the EnHAnce PEEK Bunion System, submitted by Nvision Biomedical Technologies of San Antonio, Texas, under 510(k) number K262098. The application was received June 22, 2026. The device falls under 21 CFR 888.3030, classification product code HRS, with the orthopedic medical specialty and orthopedic review panel. A SESE decision is a 510(k) clearance, not a PMA approval.
The public record identifies the submission type as Special and states that it was not reviewed by a third party, was not a combination product, and had no authorized predetermined change control plan. The available excerpts do not describe the specific device components, materials beyond the trade name, or the predicate comparison supporting equivalence; those details would sit in the linked summary document, which was not provided here. No clinical or performance data are available in the source.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Orthopedic
- Decision date
- Sep 18, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K262098
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Nvision Biomedical Technologies
- Product code
- HRS
- Decision code
- SESE
- Decision date
- Sep 18, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Plate, Fixation, Bone.
- Applicant
- Nvision Biomedical Technologies
- Product code
- HRS
- FDA device class
- 2
FDA decision timeline
K262098 received
Application receipt date recorded by FDA.
K262098 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code HRS
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
HERO Sternal Closure SystemK262939 | Hero Orthopedics, LLC | 510(k) clearance | Nov 2, 2026 | FDA |
| ARTHREX, INC. | 510(k) clearance | Oct 29, 2026 | FDA | |
| Skeletal Dynamics, Inc. | 510(k) clearance | Oct 26, 2026 | FDA | |
ANTHEM Fracture SystemK262779 | GLOBUS MEDICAL, INC. | 510(k) clearance | Oct 23, 2026 | FDA |
Tempo Plating SystemK263407 | Pace Surgical | 510(k) clearance | Oct 23, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Nvision Biomedical Technologies
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- San Antonio, TX
Sources and methodology
- Original FDA record: K262098
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


